Experimental agents GLP-1/glucagon receptor (GLP1R/GCR) and GLP-1/glucose-dependent insulinotropic peptide receptor (GLP1R/GIPR) dual agonists Various drugs, as noted above, originally created for the treatment of DM2, have shown promise for the treatment of NAFLD and NASH, due to their metabolic effects in lipid and glucose metabolism
The underlying peptide remains tirzepatide in all cases
No claims are made that results are guaranteed to be the same
Clinicians should engage patients in shared decision-making regarding treatment duration, considering individual response, tolerability, cost, and patient preferences
Serum multiplex cytokine panels revealed statistically significant changes in IL-2, IL-5, IL-6, and IL-8 levels in ALS patients depending on disease status at each visit